Where is human-based cellular pharmaceutical R&D taking us in cartilage regeneration?
- 6 March 2020
- journal article
- review article
- Published by Springer Nature in 3 Biotech
- Vol. 10 (4) , 1-13
Abstract
Lately, cellular-based cartilage joint therapies have gradually gained more attention, which leads to next generation bioengineering approaches in the development of cell-based medicinal products for human use in cartilage repair. The greatest hurdles of chondrocyte-based cartilage bioengineering are: (i) preferring the cell source; (ii) differentiation and expansion processes; (iii) the time necessary for chondrocyte expansion pre-implantation; and (iv) fixing the chondrocyte count in accordance with the lesion surface area of the patient in question. The chondrocyte presents itself to be the focal starting material for research and development of bioengineered cartilage-based medicinal products which promise the regeneration and restoration of non-orthopedic cartilage joint defects. Even though chondrocytes seem to be the first choice, inevitable complications related to proliferation, dedifferentation and redifferentiation are probable. Detailed studies are a necessity to fully investigate detailed culturing conditions, the chondrogenic strains of well-defined phenotypes and evaluation of the methods to be used in biomaterial production. Despite a majority of the current methods which aid amelioration of joint functionality, they are insufficient in fully restoring the natural structure and composition of the joint cartilage. Hence current studies have trended towards gene therapy, mesenchymal stem cells and tissue engineering practices. There are many studies addressing the outcomes of chondrocytes in the clinical scene, and many vital biomaterials have been developed for structuring the bioengineered cartilage. This study aims to convey to the audience the practical significance of chondrocyte-based clinical applications.Keywords
This publication has 129 references indexed in Scilit:
- Cartilage tissue engineering using differentiated and purified induced pluripotent stem cellsProceedings of the National Academy of Sciences, 2012
- Extracellular matrix deposited by synovium‐derived stem cells delays replicative senescent chondrocyte dedifferentiation and enhances redifferentiationJournal of Cellular Physiology, 2011
- Human Embryonic Stem Cell–Derived Mesoderm-like Epithelium Transitions to Mesenchymal Progenitor CellsTissue Engineering Part A, 2009
- Extraction techniques for the decellularization of tissue engineered articular cartilage constructsBiomaterials, 2009
- Modular injectable matrices based on alginate solution/microsphere mixtures that gel in situ and co-deliver immunomodulatory factorsActa Biomaterialia, 2009
- Growth factor gradients via microsphere delivery in biopolymer scaffolds for osteochondral tissue engineeringJournal of Controlled Release, 2009
- Engineering of Functional Cartilage Tissue Using Stem Cells from Synovial Lining: A Preliminary StudyClinical Orthopaedics and Related Research, 2008
- Induction of Pluripotent Stem Cells from Mouse Embryonic and Adult Fibroblast Cultures by Defined FactorsCell, 2006
- Technology Insight: adult stem cells in cartilage regeneration and tissue engineeringNature Clinical Practice Rheumatology, 2006
- Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statementCytotherapy, 2006